Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

India Tweaks More Trial Rules But Can It Change The Narrative?

Executive Summary

India has tweaked another set of trial rules including one that capped the number of trials per investigator as it seeks to clear the logjam of regulatory requirements that has been stifling the clinical research segment in the country. Much though could depend on actual implementation and it remains to be seen if such measures can alter the course of sector.


Related Content

Indian Clinical Research Sector: Hope And Despair Amid Shutdowns
Semler Dirty Data: EMA Suspends Over 200 Products; Stings Indian CROs
New Orders Set To Clear Indian Trial Bottlenecks ‘Soon’
US NIH Resumes Indian Trials But Keen On 'Elaborations' Of Rules
India Deregulates Academic Clinical Trials
India Tweaks Audio-Visual Norms For Trials
Indian CRO segment in the throes of a shakeout?
India limits trials per investigator but finite expert pool a concern